Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 70207
Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkinâ€™s lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system.
In addition to issued and pending patents, we also have â€œOrphan Drugâ€ designations for SGX301 in the U.S.
The exclusive license includes rights to several issued US patents, including U.S. patent numbers 6,867,235 and 7,122,518, among other domestic and foreign patent applications.
IPSCIO Record ID: 113052
The company is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments BioTherapeutics and Vaccines/BioDefense.
The Companyâ€™s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€), proprietary formulations of oral beclomethasone 17, 21-dipropionate (â€œBDPâ€) for the prevention/treatment of gastrointestinal (â€œGIâ€) disorders characterized by severe inflammation, including pediatric Crohnâ€™s disease (SGX203) and acute radiation enteritis (SGX201), and itâ€™s novel innate defense regulator (â€œIDRâ€) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
The Companyâ€™s Vaccines/BioDefense business segment includes active development programs for RiVaxâ„¢, its ricin toxin vaccine candidate, VeloThraxâ„¢, an anthrax vaccine candidate, OrbeShieldÂ®, a GI acute radiation syndrome (â€œGI ARSâ€) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVaxÂ®, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Company will attempt to advance the development of RiVaxâ„¢ to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) and NIAID to advance the development of OrbeShieldÂ® for the treatment of GI ARS.
IPSCIO Record ID: 1634